REG - AstraZeneca PLC - AstraZeneca divests Seroquel rights: US and Canada

AstraZenecaAnnouncement

03/12/2019 07:05

RNS Number : 4612V
AstraZeneca PLC
03 December 2019
 


3 December 2019 07:00 GMT
 
AstraZeneca divests rights to Seroquel and Seroquel XR in the US and Canada
 
Sale to Cheplapharm supports AstraZeneca's focus on main therapy areas
 
AstraZeneca has agreed to sell the commercial rights to Seroquel (quetiapine fumarate immediate release) and Seroquel XR (quetiapine fumarate extended release) in the US and Canada to Cheplapharm Arzneimittel GmbH (Cheplapharm). Seroquel and Seroquel XR, used primarily to treat schizophrenia and bipolar disorder, have lost their compound patent protection in the US and Canada.
 
Ruud Dobber, Executive Vice President, BioPharmaceuticals Business Unit, said: "This divestment supports our strategy of reducing the number of mature medicines to enable reinvestment in our main therapy areas. Cheplapharm recently agreed to acquire the commercial rights to Seroquel and Seroquel XR in most European markets and Russia from AstraZeneca and this new agreement will help ensure continued patient access to this important established medicine in North America as well."
 
AstraZeneca will continue to manufacture and supply Seroquel and Seroquel XR to Cheplapharm during a transition period.
 
Financial considerations
Cheplapharm will make an upfront payment of $35m to AstraZeneca and may also make future sales-contingent payments of up to $6m. Income arising from the upfront and future payments will be reported in AstraZeneca's financial statements within Other Operating Income & Expense. In 2018, Seroquel generated sales of $36m in the markets covered by this agreement, while Seroquel XR generated $79m. The agreement does not impact the Company's financial guidance for 2019. As there were no closing conditions to the divestment, the agreement became effective upon signing.
 
Pursuant to Listing Rule 10.4.1R (notification of class 2 transactions), the gross book value of assets subject to the divestment as at 31 December 2018 was nil. In the year to 31 December 2018, the aggregate profit before tax attributable to Seroquel and Seroquel XR in the relevant territories were $108m. The consideration will be paid in cash and the proceeds used for general corporate purposes.
 
About Seroquel
Seroquel and Seroquel XR are atypical anti-psychotic medicines with antidepressant properties. The main indications for Seroquel are the treatment of schizophrenia and bipolar disorder. Seroquel XR is also approved in some markets for major depressive disorder and generalised anxiety disorder.
 
AstraZeneca previously divested the rights to Seroquel and Seroquel XR in the UK, Japan and other major international markets. AstraZeneca also agreed to divest the rights to the medicines in Europe (excluding the UK) and Russia to Cheplapharm earlier in 2019, a transaction that is expected to complete in the fourth quarter of 2019, subject to customary closing conditions and regulatory clearances.
 
About AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.



Media Relations












Gonzalo Viña






+44 203 749 5916




Rob Skelding


Oncology


+44 203 749 5821




Rebecca Einhorn


Oncology


+1 301 518 4122




Matt Kent


BioPharmaceuticals


+44 203 749 5906




Jennifer Hursit


Other


+44 203 749 5762




Christina Malmberg Hägerstrand


Sweden


+46 8 552 53 106




Michele Meixell


US


+1 302 885 2677


















Investor Relations












Thomas Kudsk Larsen






+44 203 749 5712




Henry Wheeler


Oncology


+44 203 749 5797




Christer Gruvris


BioPharmaceuticals (Cardiovascular, Metabolism)


+44 203 749 5711




Nick Stone


BioPharmaceuticals (Renal) Environmental, Social and Governance


+44 203 749 5716




Josie Afolabi


BioPharmaceuticals (Respiratory)
Other medicines


+44 203 749 5631




Craig Marks


Finance
Fixed income


+44 7881 615 764




Jennifer Kretzmann


Corporate access
Retail investors


+44 203 749 5824




US toll-free






+1 866 381 72 77



 
Adrian Kemp

Company Secretary
AstraZeneca PLC




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCQXLBBKLFBFBE